<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445911</url>
  </required_header>
  <id_info>
    <org_study_id>KQ-791-02</org_study_id>
    <nct_id>NCT02445911</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of KQ-791 in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaneq Bioscience Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaneq Bioscience Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the Change From Baseline in Fasting Blood Glucose Between KQ-791 and Placebo</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Data table is change from baseline in Fasting Blood Glucose. Statistical Analysis includes results for difference in Change from baseline in Fasting Blood Glucose Between KQ-791 and Placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Treatment-Emergent Adverse Events</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Quantitative Insulin Sensitivity Check Index (QUICKI)</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>QUICKI = 1/(log FPG + log FPI) where FPG = fasting plasma glucose (mg/dL); FPI = fasting plasma insulin (estimated based on fasting serum insulin; (μIU/mL)). Lower numbers reflect greater insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Insulin Sensitivity Index (ISI)</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Insulin sensitivity index (ISI) composite using Matsuda's whole body insulin sensitivity, ISI [composite] = 10000/√[(FPG x FPI)x(Mean Glucose 0-120min in MMTT x Mean Insulin 0-120 min in MMTT)] where MMTT is a mixed meal tolerance test, Hour 0=just prior dosing. Lower values indicate greater insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Beta Cell Function</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Evaluated as beta index = (Insulin Area Under the Effect Curve (AUEC) in MMTT/Glucose AUEC in MMTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disposition Index</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Disposition Index evaluated as beta index x ISI [composite]. Lower values of the disposition index suggests loss of function of beta cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Hepatic Insulin Resistance Index</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Hepatic Insulin Resistance Index will be evaluated as Glucose AUEC from zero to 30 minutes (AUEC0-30min) in MMTT x Insulin AUEC0-30 min in MMTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 7-point Average Blood Glucose</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>The 7-points measured were just prior to each meal and 90 minutes after the start of the meal and approximately bedtime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Glucose</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hours Post-Dose (AUC0-24)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the Maximum Measured Plasma Concentration (Tmax)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUCtau)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady-state (Cmax_ss)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the Maximum Measured Plasma Concentration at Steady-state (Tmax_ss)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (AI)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
    <description>Based on AUC (RacAUC), where RacAUC is the ratio of AUC during a dosing interval following the last dose over the loading dose (first dose)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>KQ-791 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KQ-791 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose on day 1, followed by a daily dose for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KQ-791 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending doses matching KQ-791 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KQ-791</intervention_name>
    <description>Capsules administered orally</description>
    <arm_group_label>KQ-791 Dose 1</arm_group_label>
    <arm_group_label>KQ-791 Dose 2</arm_group_label>
    <arm_group_label>KQ-791 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of Type 2 Diabetes Mellitus (T2DM)

          -  Be an adult between the ages of 18 (19 for Lincoln site) and 70 years

          -  Female participants must be of non-childbearing potential, and must be either 1)
             postmenopausal with amenorrhea for at least 1 year prior to the first dose and
             Follicle Stimulating Hormone (FSH) serum levels consistent with postmenopausal status,
             or 2) have undergone one of the following sterilization procedures at least 6 months
             prior to the first dose:

               -  hysteroscopic sterilization

               -  bilateral tubal ligation or bilateral salpingectomy

               -  hysterectomy

               -  bilateral oophorectomy

          -  Non-vasectomized males must agree to use a condom with spermicide or abstain from
             sexual intercourse during the study until 100 days beyond the last dose of study drug.
             (No restrictions are required for a vasectomized male provided his vasectomy has been
             performed 4 months or more prior to first dosing. A male who has been vasectomized
             less than 4 months prior to first dosing must follow the same restrictions as a
             non-vasectomized male)

          -  Males must agree to not donate sperm during the study and for 100 days following the
             last dose

          -  Have an HbA1c value between 7.0-10.0%

          -  Be on a stable treatment regimen of metformin, with or without diet/exercise, for at
             least 8 weeks

          -  Weigh 60 kilograms (kg) or more at screening and have a body mass index (BMI) greater
             than or equal to (≥) 25.0 and less than or equal to (≤) 40.0 kilograms/meters squared
             (kg/m2)

          -  Have laboratory test results within the normal range for T2DM population, or with
             abnormalities deemed clinically insignificant. Urine protein levels must be within
             normal limits

          -  Absence of active diabetic retinopathy (Stage 2 or greater by the International
             Clinical Disease Severity Scale for Diabetic Retinopathy)

          -  Are willing to comply with specific dietary restrictions (that is, [i] able to fast
             overnight for at least 8-12 hours on several days and [ii] able to consume the
             standard meals provided during specified confinement days)

          -  Have given written consent to allow collection of samples for Peripheral Blood
             Mononuclear Cells (PBMC) analysis and for possible biomarkers/safety analysis

          -  Have given written informed consent approved by the institutional review board (IRB)
             governing the site

        Exclusion Criteria:

          -  Are currently enrolled in a clinical trial involving an investigational product or
             off-label use of a drug or device, or are concurrently enrolled in any other type of
             medical research judged not to be scientifically or medically compatible with this
             study

          -  Participated (defined as the last dose of study drug) within 30 days prior to dosing
             in a clinical trial involving an investigational product or non-approved use of a drug
             with a short half-life or within 5 half-lives of an investigational product with a
             half-life longer than 6 days

          -  - Have a (QTcF) greater than (&gt;) 450 milliseconds (msec), or clinical significant
             hypokalemia, a family history of long QT syndrome or any abnormality in the 12-lead
             Electrocardiogram (ECG)

          -  Abnormal blood pressure (sitting) defined as diastolic blood pressure &gt; 95 or less
             than (&lt;) 50 millimeter of mercury (mmHg) and/or systolic blood pressure &gt; 160 or &lt; 90
             mmHg

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs

          -  Show evidence of regular use of known drugs of abuse and/or positive findings on
             urinary drug screening

          -  Evidence of human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C
             and/or positive results at screening for the respective antibodies for HIV, hepatitis
             B surface antigen (HBsAg), or hepatitis C antibodies (HCV)

          -  Have anemia that would interfere with the trial or have donated ≥500 mL of blood
             within 56 days before the first dose or have donated plasma within 7 days before the
             first dose or provided any blood donation within last 30 days

          -  Have an average weekly alcohol intake that exceeds 14 units per week (males) and 7
             units per week (females) [1 unit = 12 ounces (oz) or 360 mL of beer, 5 oz or 150 mL of
             wine, or 1.5 oz or 45 mL of distilled spirits] or are unwilling to stop alcohol
             consumption 48 hours prior to the first dosing and throughout the study

          -  Consume more than 10 cigarettes per day or the equivalent or are unable or unwilling
             to adhere to restricted smoking policies

          -  Have had &gt;1 episode of documented severe hypoglycemia within last 6 months or are
             currently diagnosed as having hypoglycemia unawareness

          -  Have any of the following clinical laboratory test results:

               -  estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2 (impaired renal
                  function)

               -  alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels &gt; 1.5
                  times (x) the upper limit of normal (ULN)

               -  triglycerides (TG) &gt; 500 milligrams/deciliter (mg/dL)

          -  Have used insulin or other glycemic control medications, except metformin, for
             diabetic control within 3 months

          -  Intend to use non-steroidal anti-inflammatory drugs (except aspirin) and drugs known
             to prolong QT interval, herbal products, or vitamin supplements that change glucose
             levels. The following medications are allowed for participants:

               -  drugs for treatment of hypertension or lipid disorders (except bile acid resins,
                  niacin or fish oils), platelet inhibitors, and on stable dose for 12 weeks prior
                  to first dose

               -  thyroid replacement therapy, proton pump inhibitors, antidepressants,
                  antihistamines, regularly taken over-the-counter (OTC) and anti-emetics that do
                  not cause a corrected QT interval (QTc) prolongation, provided such drugs are not
                  specifically excluded

               -  hormonal replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: daniel.bouthillier@Kaneq.ca</last_name>
    <role>Study Director</role>
    <affiliation>Kaneq Bioscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>October 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>KQ-791 Dose 1</title>
          <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
        </group>
        <group group_id="P2">
          <title>KQ-791 Dose 2</title>
          <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
        </group>
        <group group_id="P3">
          <title>KQ-791 Dose 3</title>
          <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>KQ-791 Dose 1</title>
          <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
        </group>
        <group group_id="B2">
          <title>KQ-791 Dose 2</title>
          <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
        </group>
        <group group_id="B3">
          <title>KQ-791 Dose 3</title>
          <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in the Change From Baseline in Fasting Blood Glucose Between KQ-791 and Placebo</title>
        <description>Data table is change from baseline in Fasting Blood Glucose. Statistical Analysis includes results for difference in Change from baseline in Fasting Blood Glucose Between KQ-791 and Placebo.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <population>Pharmacodynamic (PD) population incudes all 81 participants</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Change From Baseline in Fasting Blood Glucose Between KQ-791 and Placebo</title>
          <description>Data table is change from baseline in Fasting Blood Glucose. Statistical Analysis includes results for difference in Change from baseline in Fasting Blood Glucose Between KQ-791 and Placebo.</description>
          <population>Pharmacodynamic (PD) population incudes all 81 participants</population>
          <units>mg/dL milligrams per deciliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.28" spread="22.99"/>
                    <measurement group_id="O2" value="-3.93" spread="30.63"/>
                    <measurement group_id="O3" value="0.67" spread="30.82"/>
                    <measurement group_id="O4" value="3.17" spread="23.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-6.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.75</ci_lower_limit>
            <ci_upper_limit>10.18</ci_upper_limit>
            <estimate_desc>Least-squares means have baseline and site as covariates. Placebo was the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-2.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.65</ci_lower_limit>
            <ci_upper_limit>13.72</ci_upper_limit>
            <estimate_desc>Least-squares means have baseline and site as covariates. Placebo was the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-5.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.97</ci_lower_limit>
            <ci_upper_limit>11.88</ci_upper_limit>
            <estimate_desc>Least-squares means have baseline and site as covariates. Placebo was the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Treatment-Emergent Adverse Events</title>
        <time_frame>Baseline to Day 29</time_frame>
        <population>PD population includes all 81 participants</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Treatment-Emergent Adverse Events</title>
          <population>PD population includes all 81 participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
        <description>QUICKI = 1/(log FPG + log FPI) where FPG = fasting plasma glucose (mg/dL); FPI = fasting plasma insulin (estimated based on fasting serum insulin; (μIU/mL)). Lower numbers reflect greater insulin resistance.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <population>PD population includes all 81 participants</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
          <description>QUICKI = 1/(log FPG + log FPI) where FPG = fasting plasma glucose (mg/dL); FPI = fasting plasma insulin (estimated based on fasting serum insulin; (μIU/mL)). Lower numbers reflect greater insulin resistance.</description>
          <population>PD population includes all 81 participants</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0043" spread=".012"/>
                    <measurement group_id="O2" value=".003" spread=".013"/>
                    <measurement group_id="O3" value=".005" spread=".0125"/>
                    <measurement group_id="O4" value="-.0012" spread=".0116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Insulin Sensitivity Index (ISI)</title>
        <description>Insulin sensitivity index (ISI) composite using Matsuda's whole body insulin sensitivity, ISI [composite] = 10000/√[(FPG x FPI)x(Mean Glucose 0-120min in MMTT x Mean Insulin 0-120 min in MMTT)] where MMTT is a mixed meal tolerance test, Hour 0=just prior dosing. Lower values indicate greater insulin resistance.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <population>Includes all subjects who receive at least one dose of study drug and have evaluable ISI data.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Insulin Sensitivity Index (ISI)</title>
          <description>Insulin sensitivity index (ISI) composite using Matsuda's whole body insulin sensitivity, ISI [composite] = 10000/√[(FPG x FPI)x(Mean Glucose 0-120min in MMTT x Mean Insulin 0-120 min in MMTT)] where MMTT is a mixed meal tolerance test, Hour 0=just prior dosing. Lower values indicate greater insulin resistance.</description>
          <population>Includes all subjects who receive at least one dose of study drug and have evaluable ISI data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0043" spread="0.7345"/>
                    <measurement group_id="O2" value="-.0585" spread="0.586"/>
                    <measurement group_id="O3" value="0.145" spread="0.697"/>
                    <measurement group_id="O4" value="-0.112" spread="0.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Beta Cell Function</title>
        <description>Evaluated as beta index = (Insulin Area Under the Effect Curve (AUEC) in MMTT/Glucose AUEC in MMTT)</description>
        <time_frame>Baseline to Day 29</time_frame>
        <population>PD population includes all 81 participants</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Beta Cell Function</title>
          <description>Evaluated as beta index = (Insulin Area Under the Effect Curve (AUEC) in MMTT/Glucose AUEC in MMTT)</description>
          <population>PD population includes all 81 participants</population>
          <units>(hr*μIU/mL(hr*mg/dL))</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00098" spread="0.0866"/>
                    <measurement group_id="O2" value="0.012" spread="0.0585"/>
                    <measurement group_id="O3" value="0.0535" spread="0.1099"/>
                    <measurement group_id="O4" value="0.0027" spread="0.0491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disposition Index</title>
        <description>Disposition Index evaluated as beta index x ISI [composite]. Lower values of the disposition index suggests loss of function of beta cells.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <population>Includes all subjects who receive at least one dose of study drug and have evaluable data for disposition index.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disposition Index</title>
          <description>Disposition Index evaluated as beta index x ISI [composite]. Lower values of the disposition index suggests loss of function of beta cells.</description>
          <population>Includes all subjects who receive at least one dose of study drug and have evaluable data for disposition index.</population>
          <units>Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.128"/>
                    <measurement group_id="O2" value="0.023" spread="0.147"/>
                    <measurement group_id="O3" value="0.084" spread="0.185"/>
                    <measurement group_id="O4" value="0.008" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Hepatic Insulin Resistance Index</title>
        <description>Hepatic Insulin Resistance Index will be evaluated as Glucose AUEC from zero to 30 minutes (AUEC0-30min) in MMTT x Insulin AUEC0-30 min in MMTT</description>
        <time_frame>Baseline to Day 29</time_frame>
        <population>PD population includes all 81 participants</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Hepatic Insulin Resistance Index</title>
          <description>Hepatic Insulin Resistance Index will be evaluated as Glucose AUEC from zero to 30 minutes (AUEC0-30min) in MMTT x Insulin AUEC0-30 min in MMTT</description>
          <population>PD population includes all 81 participants</population>
          <units>(hr*mg/dL)*(hr*μUI/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.51" spread="495.81"/>
                    <measurement group_id="O2" value="255.53" spread="484.27"/>
                    <measurement group_id="O3" value="93.17" spread="462.25"/>
                    <measurement group_id="O4" value="56.90" spread="482.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 7-point Average Blood Glucose</title>
        <description>The 7-points measured were just prior to each meal and 90 minutes after the start of the meal and approximately bedtime.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <population>PD population includes all 81 participants</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 7-point Average Blood Glucose</title>
          <description>The 7-points measured were just prior to each meal and 90 minutes after the start of the meal and approximately bedtime.</description>
          <population>PD population includes all 81 participants</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.04" spread="20.76"/>
                    <measurement group_id="O2" value="0.35" spread="35.74"/>
                    <measurement group_id="O3" value="-2.61" spread="38.66"/>
                    <measurement group_id="O4" value="4.44" spread="27.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Glucose</title>
        <time_frame>Baseline to Day 29</time_frame>
        <population>PD population includes all 81 participants</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Glucose</title>
          <population>PD population includes all 81 participants</population>
          <units>hr*mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.23" spread="281.62"/>
                    <measurement group_id="O2" value="-0.086" spread="484.712"/>
                    <measurement group_id="O3" value="-35.60" spread="524.57"/>
                    <measurement group_id="O4" value="58.61" spread="381.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c</title>
        <time_frame>Baseline to Day 29</time_frame>
        <population>Includes all subjects who receive at least one dose of study drug and have evaluable HbA1c data.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c</title>
          <population>Includes all subjects who receive at least one dose of study drug and have evaluable HbA1c data.</population>
          <units>Percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.185" spread="0.3265"/>
                    <measurement group_id="O2" value="0.025" spread="0.4303"/>
                    <measurement group_id="O3" value="-0.315" spread="0.5174"/>
                    <measurement group_id="O4" value="-0.0333" spread="0.3343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hours Post-Dose (AUC0-24)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose</time_frame>
        <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-24.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hours Post-Dose (AUC0-24)</title>
          <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-24.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14372.2" spread="2882.69"/>
                    <measurement group_id="O2" value="29011.2" spread="6030.57"/>
                    <measurement group_id="O3" value="140990.4" spread="47460.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose</time_frame>
        <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Cmax.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="747.56" spread="163.768"/>
                    <measurement group_id="O2" value="1484.74" spread="341.712"/>
                    <measurement group_id="O3" value="7204.70" spread="2517.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of the Maximum Measured Plasma Concentration (Tmax)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose</time_frame>
        <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Time of the Maximum Measured Plasma Concentration (Tmax)</title>
          <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Tmax.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" spread="3.251"/>
                    <measurement group_id="O2" value="5.05" spread="3.395"/>
                    <measurement group_id="O3" value="9.42" spread="8.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUCtau)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
        <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUCtau.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUCtau)</title>
          <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUCtau.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76863.5" spread="34469.47"/>
                    <measurement group_id="O2" value="25754.9" spread="13130.00"/>
                    <measurement group_id="O3" value="150681.0" spread="55372.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration at Steady-state (Cmax_ss)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
        <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Cmax_ss.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration at Steady-state (Cmax_ss)</title>
          <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Cmax_ss.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="657.82" spread="238.542"/>
                    <measurement group_id="O2" value="1164.65" spread="568.489"/>
                    <measurement group_id="O3" value="7221.37" spread="2672.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of the Maximum Measured Plasma Concentration at Steady-state (Tmax_ss)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
        <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Tmax_ss.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Time of the Maximum Measured Plasma Concentration at Steady-state (Tmax_ss)</title>
          <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Tmax_ss.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" spread="5.00"/>
                    <measurement group_id="O2" value="5.43" spread="5.69"/>
                    <measurement group_id="O3" value="3.83" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Half-life (t1/2)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
        <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute t1/2.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Half-life (t1/2)</title>
          <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute t1/2.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.095" spread="79.378"/>
                    <measurement group_id="O2" value="184.386" spread="36.385"/>
                    <measurement group_id="O3" value="178.018" spread="28.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Index (AI)</title>
        <description>Based on AUC (RacAUC), where RacAUC is the ratio of AUC during a dosing interval following the last dose over the loading dose (first dose)</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29</time_frame>
        <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AI.</population>
        <group_list>
          <group group_id="O1">
            <title>KQ-791 Dose 1</title>
            <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O2">
            <title>KQ-791 Dose 2</title>
            <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
          <group group_id="O3">
            <title>KQ-791 Dose 3</title>
            <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Index (AI)</title>
          <description>Based on AUC (RacAUC), where RacAUC is the ratio of AUC during a dosing interval following the last dose over the loading dose (first dose)</description>
          <population>Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AI.</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.537"/>
                    <measurement group_id="O2" value="9.37" spread="4.934"/>
                    <measurement group_id="O3" value="12.01" spread="6.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>KQ-791 Dose 1</title>
          <description>Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29
KQ-791: Capsules administered orally</description>
        </group>
        <group group_id="E2">
          <title>KQ-791 Dose 2</title>
          <description>Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days
KQ-791: Capsules administered orally</description>
        </group>
        <group group_id="E3">
          <title>KQ-791 Dose 3</title>
          <description>Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days
KQ-791: Capsules administered orally</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Multiple ascending doses matching KQ-791 dose
Placebo: Capsules administered orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Glomuerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Written consent</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gosse Bruinsma</name_or_title>
      <organization>Kaneq Bioscience Limited</organization>
      <phone>1-613-800-0955</phone>
      <email>gosse.bruinsma@kaneqbioscience.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

